Vimpat (lacosamide): Established seizure therapy for adults and children

Responsible: ad hoc news Classics & Long-sellers Desk. Reviewed prior to publication on June 12, 2026 at 10:47 PM ET. Details in the imprint.

Vimpat (generic name: lacosamide) is one of UCB's established anti-seizure medicines, used for the treatment of focal-onset seizures in adults, adolescents, and children as young as 4 years old in the United States. It has been part of the company's neurology portfolio for years and is available in several formulations, including oral tablets, oral solution, and an intravenous injection for hospital use. For US patients living with epilepsy, Vimpat is typically used either as an add-on (adjunctive) therapy or as monotherapy, depending on age group and seizure type, following the indications approved by the US Food and Drug Administration (FDA).

How Vimpat is positioned in epilepsy care

Vimpat is indicated in the US for the treatment of focal-onset seizures in patients 4 years of age and older, both as monotherapy and adjunctive therapy, according to the approved prescribing information. In adults with partial-onset (now called focal-onset) seizures, clinical studies have shown that lacosamide can reduce seizure frequency when added to existing anti-seizure regimens. The drug works by selectively enhancing the slow inactivation of voltage-gated sodium channels, a mechanism that is distinct from several older sodium channel-blocking anti-seizure medicines. This selective slow-inactivation effect is designed to stabilize hyperexcitable neuronal membranes while aiming to limit some of the broader effects seen with traditional fast inactivation sodium channel blockers.

UCB offers Vimpat in multiple strengths to allow neurologists to titrate the dose gradually and tailor therapy to the individual patient. In the US, film-coated tablets are typically available in strengths such as 50 mg, 100 mg, 150 mg, and 200 mg, while the oral solution provides a liquid option for patients who have difficulty swallowing tablets or for younger children who need weight-based dosing. The intravenous formulation is used mainly in hospital or acute care settings, for example when patients are unable to take oral medication. Standard titration schedules usually start at a lower daily dose and increase over several weeks to a maintenance dose, with the exact dosing strategy guided by the prescribing information and the treating physician's judgment.

As with other prescription anti-seizure medicines, Vimpat has a safety profile that must be carefully considered. Common adverse reactions reported in clinical trials include dizziness, headache, nausea, and diplopia (double vision). The prescribing information also carries warnings and precautions, such as the risk of cardiac rhythm and conduction abnormalities, including PR interval prolongation and atrioventricular block in susceptible patients. Physicians are advised to consider baseline ECG in patients with known cardiac conduction issues or on concomitant medications that prolong PR interval. There is also a class-related warning for anti-seizure medicines about the risk of suicidal thoughts and behavior, and patients and caregivers are advised to monitor for mood changes and report concerning symptoms to their healthcare provider.

Vimpat plays a significant role in UCB's focus on epilepsy, complementing other neurology products in its portfolio. The company has highlighted its long-term commitment to epilepsy care in various investor and pipeline updates, underlining the goal of providing multiple therapeutic options for different seizure types and patient needs. For many adult patients whose seizures remain uncontrolled on older treatments, lacosamide has been one of the modern options added over the past decade to broaden the choices available to neurologists. While individual response varies and not all patients achieve seizure freedom, real-world experience and controlled studies have been important in shaping how lacosamide is used in US clinical practice.

From a market perspective, Vimpat competes with a range of branded and generic anti-seizure medicines, including both older agents and newer therapies from several manufacturers. Pricing in the US reflects its status as a branded prescription medicine, and net costs to patients depend heavily on insurance coverage, copay assistance, and pharmacy benefit design. Payers and clinicians often weigh the drug's efficacy, tolerability, and dosing flexibility against alternative options when deciding on treatment plans. For some patients, features such as the availability of both oral and intravenous forms and the possibility of once- or twice-daily dosing, depending on regimen, may influence real-world convenience, particularly when transitioning between inpatient and outpatient care.

For US consumers and caregivers, the practical question is often how Vimpat fits within a broader epilepsy management strategy. Neurologists typically consider seizure type, age, comorbidities, concomitant medications, and potential drug-drug interactions when selecting lacosamide or an alternative therapy. They also weigh the need for slow titration to minimize side effects against the urgency of controlling seizures. Patients are generally advised not to stop Vimpat abruptly due to the risk of increased seizure frequency, and any changes to dosing are usually managed gradually under medical supervision. Counseling on common side effects like dizziness is essential, particularly regarding driving or operating machinery until the individual knows how the medicine affects them. Because lacosamide can interact with other central nervous system (CNS) active drugs, pharmacists in retail and hospital settings often play a key role in double-checking medication lists and reinforcing counseling at the point of dispensing.

Within UCB's broader strategy, established products like Vimpat help support ongoing investment in newer pipeline candidates in neurology and immunology. While detailed product-level sales figures for the latest period may vary by source and reporting habits, management presentations have repeatedly emphasized the importance of the epilepsy franchise as a pillar of the company's revenue base and expertise. Exactly how revenue is allocated across individual medicines may change over time as patents evolve and competition from generics increases, but long-standing brands typically contribute a mix of direct sales and experience-based credibility with treating physicians.

For investors following the company, the performance of long-seller therapies in epilepsy sits alongside newer launches and late-stage pipeline news in shaping the overall profile. Shares of UCB (BE0003739530, ticker UCBJY) last traded over the counter in the US, with pricing information available via US quotation services and the company's investor relations materials as of recent sessions.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.